The beleaguered direct-to-consumer (DTC) gene testing company 23andMe just cannot catch a break. And its problems seem to be largely of its own making.
Last year, the company stopped responding to the FDA’s letters. In response, the FDA finally sent a cease-and-desist letter that basically restricted the company to providing raw data and doing ancestry tests. Sales fell by 50%. CEO Anne Wojcicki has been putting a brave face on this, calling it “a really good experience for 23andMe because it’s taking us up a level,” and hired four executives with healthcare backgrounds.
Then Vox, which launched in April as a fact-based website covering both news and background, started looking into some of the possible issues that DTC testing can raise, and published two articles on September 9th. The general overview was:
The dramatic case study was headlined:
The author explained that through his 23andMe gene test, he had discovered a previously unknown half brother — his father’s previously unacknowledged or unknown son. Then the rest of his family found out.
Years of repressed memories and emotions uncorked and resulted in tumultuous times that have torn my nuclear family apart. My parents divorced. No one is talking to my dad. We’re not anywhere close to being healed yet and I don’t know how long it will take to put the pieces back together.
Vox also revealed that 23andMe was about to move from an opt-in to an opt-out model of revealing close relationships.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.